Shaping the future of animal health
Virbac group
Responsibility contact
For more information about our actions in this field, please e-mail us: developpement.

Economic performance

Dedicated exclusively to animal health for nearly fifty years, Virbac aims to continue its development in harmony with its environment and with its workers. It also wants to ensure the continuity of the Group through sustainable and profitable growth. In 2016, Virbac returned to organic growth, up +4.4% over the year, thanks in particular to the gradual recovery in the United States and sustained performance in Europe and emerging countries.

As part of its strategy, Virbac supports its development through regular new product launches, the strength of its large portfolio and global presence reaching into all the major markets in both developed and emerging countries. This controlled-growth strategy is reflected by a steady growth in revenues and the workforce. Virbac also benefits from a stable shareholder family which favours constant and long-term progress over short-term goals. In terms of the sub-contracted production activities (licensing products or production sub-contracted to a third party), they represent more than one third of the Group’s sales in 2016, following the acquisition of Sentinel products manufactured externally over the period. The suppliers in charge of manufacturing these products are managed according to the evaluation procedures described in the G4-HR5 and G4-HR10 indicators.

Change in revenue (€ million) and Group staff numbers
Change in result for the period and market capitalisation (€ million)

Virbac sustains a policy of investment and innovation, which ensures the continuity and independence of the company. Also, thanks to controlled debt, Virbac is able to pursue internal and external growth with full independence. The resources thus deployed favour financing innovation that is oriented towards satisfying customer needs.

In 2016, resources dedicated to innovation (research, development, licensing) represented 7.6% of its sales. At the same time, the Group continues to use its investment capacity to support its development through targeted external growth (acquisitions of companies, products, active ingredients, etc.) and to finance an investment programme, particularly in industrial projects.

R&D expenses + Licensing 
(€ million)
Net debt / equity - 
Group share (%)


Figures from 2015 include funding for the acquisition of Sentinel brands in the United States.


Share on Google Share on Facebook Print current page